



State of Wisconsin  
2017 - 2018 LEGISLATURE

LRBa0106/1  
MED:jld

**ASSEMBLY AMENDMENT 4,  
TO ASSEMBLY SUBSTITUTE AMENDMENT 1,  
TO ASSEMBLY BILL 69**

March 7, 2017 - Offered by Representatives SUBECK, SARGENT and SPREITZER.

1 At the locations indicated, amend the substitute amendment as follows:

2 **1.** Page 3, line 17: after "MANUFACTURERS." insert "(a)".

3 **2.** Page 3, line 19: after "patient." insert:

4 "(b)".

5 **3.** Page 3, line 23: after that line insert:

6 "(c) During the time an eligible patient is using an investigational drug, device,  
7 or biological product as provided in this section, the manufacturer shall notify the  
8 treating physician and the eligible patient of any clinically significant finding of a  
9 known or anticipated risk or side effect that is likely related to the investigational  
10 drug, device, or biological product that becomes known to the manufacturer after the  
11 eligible patient begins using the investigational drug, device, or biological product."

12

(END)